scholarly journals Biochemical Studies of Matrix Metalloproteinase (MMP) and tissue inhibitor of Metalloproteinase (TIMP) as New Biomarkers in HCV - Chronic liver disease

2017 ◽  
Vol 1 (4) ◽  
Author(s):  
Elgzar M. Y., Elemshaty M.H., Amar E.A.T., Abdel Atty A.M.,
Keyword(s):  
Liver Disease ◽  
Matrix Metalloproteinase ◽  
Chronic Liver Disease ◽  
Group Iv ◽  
Chronic Liver ◽  
Hcv Infection ◽  
Tissue Inhibitor Of Metalloproteinase ◽  
Tissue Inhibitor ◽  
Tnf Α ◽  
New Biomarkers

The present study aimed to investigate serum levels of Matrix Metalloproteinase (MMP9) and tissue inhibitor of Metalloproteinase (TIMP-1) as new biomarkers in HCV Chronic liver disease. Patients and methods: The study included 35 patients suffering from Chronic liver disease attending at Gastro Entrology Surgical Center (GEC), Mansoura University from 2016 to 2017 and 25 healthy individuals (HI) used as control group ,the studied groups were categorized into 14 patients (9 men and 5women; mean age 53.34±9.46yrs) suffering from HCC associated with HCV infection, 11patients (9 men and 2 women; mean age 52.34±9.14yrs) suffering from LC associated with HCV infection and 10 patients (7 men and 3women; mean age 48.9 ± 12.4yrs) suffering from Chronic Hepatitis (CH). Sera of all individuals were examined for TNF-α, LDH, AFP, ALT, AST, Albumin, T.Bilirubin, GGT, MMP-9 and TIMP-1 .  Results: The obtained results showed a significant increase in serum ALT, AST, total Bilirubin and GGT and significant decrease of Albumin in liver disease groups (I, II and III) compared with Group IV. Significant increase in serum MMP9, TIMP1 in groups (I, II and III) when compared with HI group (IV). Significant correlation was recorded between MMP9 and TIMP1 in one hand and between each one with AST, T. bilirubin and Albumin concentration. Serum concentrations of TNF-α, AFP were elevated significantly in HCC patients compared to LC and CH but the difference between LC and CH was elevated significantly only (p<0.0001) in TNF-α. Significant association was recorded between TNF-α, LDH, AFP, ALT and AST Conclusion: MMP9 and TIMP1 could be used as new biomarker for evaluating disease progression of HCV-chronic liver disease

Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease

1997 ◽  
Vol 26 (6) ◽  
pp. 1213-1219 ◽  
Author(s):  
Yoshikazu Murawaki ◽  
Yujiro Ikuta ◽  
Youko Idobe ◽  
Yukisato Kitamura ◽  
Hironaka Kawasaki
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Tissue Inhibitor Of Metalloproteinase ◽  
Tissue Inhibitor

Spatial distribution of tissue inhibitor of metalloproteinase-1 mRNA in chronic liver disease

1999 ◽  
Vol 30 (3) ◽  
pp. 425-432 ◽  
Author(s):  
Yutaka Yata ◽  
Terumi Takahara ◽  
Kei Furui ◽  
Li Ping Zhang ◽  
Bo Jin ◽  
...  
Keyword(s):  
Spatial Distribution ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Tissue Inhibitor Of Metalloproteinase ◽  
Tissue Inhibitor

scholarly journals Serum Cytokine of IL-10 and IL-12 in Chronic Liver Disease: The Immune and Inflammatory Response

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Hoda Mohamed El-Emshaty ◽  
Wesam Ahmad Nasif ◽  
Ibrahim Eldsoky Mohamed
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Inflammation ◽  
Chronic Liver ◽  
Hcv Infection ◽  
Interleukin 12 ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Serum ◽  
Significant Difference ◽  
New Biomarkers

The current study was designed to investigate the potential association of serum interleukin-10 and interleukin-12 with HCV infection in chronic liver disease and to evaluate their possible role as new biomarkers in HCC development.Material and Methods. Forty-one patients suffering from chronic liver disease (33 patients harbor HCV infection and 8 are HCV-negative patients) were enrolled in the present study and histopathologically diagnosed into 15 patients with HCC, 16 patients with LC, and 10 patients with liver histology compatible with precirrhotic hepatitis (PCH). Ten patients complaining of cholecystitis were included as nondisease control. Serum levels of IL-10 and IL-12 were measured by enzyme linked immunosorbent assay (ELISA).Results. HCV-infected patients showed elevated expression of IL-10 and IL-12 compared to nondisease controls (P<0.0001) but there is no significant difference with respect to their expression in HCV-negative patients. Serum IL-10 and IL-12 were elevated significantly with disease progression (P<0.0001) and a positive correlation coefficient was detected between IL-10, IL-12 (r=0.785,P<0.0001), and transaminase values suggesting their possible role in chronic inflammation progression leading to HCC.Conclusion. IL-10 and IL-12 might be involved in chronic inflammation progression leading to HCC and their evaluation could be used as new biomarkers to reflect the degree of inflammation in HCC development.

scholarly journals Hepatitis C and Mental Health: A Global and Indian Scenario

2017 ◽  
Vol 4 (4) ◽  
Author(s):  
Dr. Moni Chaudhary
Keyword(s):  
Mental Health ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Liver Disease ◽  
Mental Health Treatment ◽  
Chronic Liver ◽  
Hcv Infection ◽  
Healthcare Team ◽  
Related Quality ◽  
End Stage

Hepatitis C virus (HCV) infection is the leading cause of chronic liver disease which affects over 150 million individuals worldwide. Without treatment, one third of patients will develop cirrhosis and complications of end-stage liver disease. In India, the majority of chronic liver disease and related deaths are attributable to hepatitis C. People with HCV infection are likely to have poorer health related quality of life, physical, mental, psychosocial and neuropsychiatric problems. These problems are challenges for management of HCV infection. Mental health treatment is considered crucial in the overall management of HCV infection. A supportive environment and a nonjudgmental healthcare team are required for optimal medical and psychological management of patients with HCV. We present a comparison between mental health of patients with HCV infection in India and globally.

HCV infection in HBsAg positive chronic liver disease

1992 ◽  
pp. 325-326 ◽  
Author(s):  
F. Fatuzzo ◽  
M. T. Mughini ◽  
B. Cacopardo ◽  
R. La Rosa ◽  
L. Nigro ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Hcv Infection

scholarly journals Chronic Hepatitis C Virus Infection After Treatment for Pediatric Malignancy

Blood ◽  
1997 ◽  
Vol 90 (3) ◽  
pp. 1315-1320 ◽  
Author(s):  
Simone Cesaro ◽  
Maria Grazia Petris ◽  
Flavio Rossetti ◽  
Riccardo Cusinato ◽  
Corrado Pipan ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Virus Infection ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Hcv Infection ◽  
Pediatric Malignancy ◽  
Infection Markers

Abstract Sera of 658 patients who had completed treatment for pediatric malignancy were analyzed by a second-generation enzyme-linked immunosorbent assay and recombinant immunoblot assay test to assess the prevalence of hepatitis C virus (HCV)-seropositivity. All HCV-seropositive patients underwent detailed clinical, laboratory, virologic, and histologic study to analyze the course of HCV infection. One hundred seventeen of the 658 patients (17.8%) were positive for HCV infection markers. Among the 117 anti-HCV+ patients, 41 (35%) were also positive for markers of hepatitis B virus infection with or without delta virus infection markers, 91 (77.8%) had previously received blood product transfusions, and 25 (21.4%) showed a normal alanine aminotransferase (ALT) level during the last 5-year follow-up (11 of them never had abnormal ALT levels). The remaining 92 patients showed ALT levels higher than the upper limit of normal range. Eighty-one of 117 (70%) anti-HCV+ patients were HCV-RNA+, with genotype 1b being present in most patients (54%). In univariate analysis, no risk factor for chronic liver disease was statistically significant. In this study, the prevalence of HCV infection was high in patients who were treated for a childhood malignancy. In about 20% of anti-HCV+ patients, routes other than blood transfusions are to be considered in the epidemiology of HCV infection. After a 14-year median follow-up, chronic liver disease of anti-HCV+ positive patients did not show progression to liver failure.

TNF-α and Growth Hormone Resistance in Patients with Chronic Liver Disease

2003 ◽  
Vol 23 (5) ◽  
pp. 229-235 ◽  
Author(s):  
Antonio Picardi ◽  
Umberto Vespasiani Gentilucci ◽  
Enrico Maria Zardi ◽  
Domenico Caccavo ◽  
Tommasangelo Petitti ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Hormone Resistance ◽  
Growth Hormone Resistance ◽  
Tnf Α
Sign in / Sign up

Export Citation Format

Share Document